Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Faculty Opinions recommendation of Enoxaparin does not ameliorate liver fibrosis or portal hypertension in rats with advanced cirrhosis. — Ralf Weiskirchen | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Faculty Opinions recommendation of Enoxaparin does not ameliorate liver fibrosis or portal hypertension in rats with advanced cirrhosis.
RW
Shared by
Ralf Weiskirchen
Faculty Opinions recommendation of Enoxaparin does not ameliorate liver fibrosis or portal hypertension in rats with advanced cirrhosis.
Dataset
en
Authors
RW
Ralf Weiskirchen
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Dataset
Faculty Opinions recommendation of Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats.
Ralf Weiskirchen
Dataset
Faculty Opinions recommendation of Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats.
Ralf Weiskirchen
,
Martin Hennenberg
DOI
10.3410/f.727762992.793547487
Year
Published
—
Language
en
Dataset Details
Link Of The Paper
https://doi.org/10.3410/f.727762992.793547487
Timeline
Created:
June 19, 2026
Dataset
Faculty Opinions recommendation of Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis.
Ralf Weiskirchen
Dataset
Faculty Opinions recommendation of Losartan prevents portal hypertension-induced, redox-mediated endothelial dysfunction in the mesenteric artery in rats.
Ralf Weiskirchen
,
Martin Hennenberg
Dataset
Faculty Opinions recommendation of Senescence of activated stellate cells limits liver fibrosis.
Ralf Weiskirchen
,
Jens Herrmann
Discussion(0)
No comments yet. Be the first to comment.